Atrial Fibrillation Market Analysis
The global atrial fibrillation market size is poised to have a promising growth over the predicted years (2017-2023). Atrial fibrillation is a rapid and irregular heartbeat which can increase the risk of heart failure, stroke, and other heart-associated complications. Atrial fibrillation may be occasional, persistent, long-standing persistent or permanent. Though this is generally not life-threatening but is a serious medical condition which at times needs emergency treatment. There are some who may have no symptoms thus being unaware of the condition till it is discovered at the time of a physical examination, while there are others that may experience different signs and symptoms. These include, palpitations, chest pain, shortness of breath, confusion, dizziness, lightheadedness, fatigue, decreased ability of exercise and weakness. Damage or abnormalities to the heart’s structure are the common causes resulting in atrial fibrillation. Some of its possible causes include sleep apnea, stress due to surgery, pneumonia or other illness, viral infections, previous heart surgery, lung diseases, sick sinus syndrome, exposure to stimulants namely alcohol, tobacco, caffeine or medications, overactive thyroid gland, heart defects a person is born with, abnormal heart valves, coronary artery disease, heart attacks and high blood pressure.
There are plentiful factors that is boosting the growth of the atrial fibrillation market. These factors as per the Market Research Future (MRFR) report include increasing occurrence of atrial fibrillation amid the geriatric population, advancements in technology, increase in penchant for catheter ablation to treat cardiac arrhythmia, increasing incidences of health cases mainly hypertension, rheumatic fever, obesity and diabetes, various lifestyle illnesses, sedentary occupations and eating habits that may cause cardiac issues. On the contrary, scarcity of skilled professionals, therapeutic expenses, and inclination for pharmaceutical medications over atrial fibrillation therapeutics may hamper the growth of the atrial fibrillation market over the predicted years.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/6520
Atrial Fibrillation Market Segmentation
MRFR report provides an extensive segmental analysis of the atrial fibrillation market on the basis of applications and devices.
Based on devices, it is segmented into non-surgical and surgical. Under surgical devices segment, EP ablation catheters will have the maximum share in the market over the predicted years.
Based on applications, the atrial fibrillation market is segmented into ambulatory wards, well-established hospitals, high-tech medical centers, electrophysiology laboratories, and cardiac centers. Of these, well-established hospitals will dominate the market over the predicted years.
Atrial Fibrillation Market Regional Analysis
By region, the atrial fibrillation market covers growth opportunities and latest trends across Americas, Europe, Asia Pacific, and Middle East and Africa. Of these, North America will command the market over the predicted years owing to increasing use of technologically advanced treatment measures and devices in the US and Canada. The atrial fibrillation market in Europe will have the second major share in the market owing to government initiatives and reimbursement policies that is expanding the market. This is inspiring the market players. The atrial fibrillation market in the APAC region is predicted to have a substantial growth over the predicted years owing to rapidly aging population highly susceptible to heart diseases coupled with growing population. Besides, the need for atrial fibrillation devices is predicted to increase due to rise in expenditure and developments in healthcare infrastructure especially in India and China that is driving the market growth.
Atrial Fibrillation Market Key Players
Leading players profiled in the atrial fibrillation market include Abbott Laboratories, Biosense Webster, AtriCure, Medtronic Plc, Boston Scientific Corporation, and others.
April 2019- A team of cardiovascular experts at the University of Miami Health System lately has opened a clinical trial which may augment treatment outcomes for those with atrial fibrillation. The Liraglutide Effect in Atrial Fibrillation (LEAF) trial is funded via NIH and accessible exclusively at UHealth. This will examine Liraglutide’s effectiveness to reduce atrial fibrillation. Earlier studies have shown how Liraglutide reduced fat tissues surrounding the heart known as catheter ablation. Now LEAF will test as to whether this fat reduction will improve the result of catheter ablation.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/atrial-fibrillation-systems-market-6520
Atrial Fibrillation Industry Update
April 2019- FDA has lately approved AliveCor KardiaMobile, a new smartphone that will help to detect tachycardia, bradycardia and atrial fibrillation and that too in just 30 seconds.